Can a pill replace the shot for weight loss?
NCT ID NCT07802899
First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time
Summary
This early trial tests an investigational pill called IBI3042, which activates the GLP-1 receptor, a target used by many weight-loss drugs. Researchers want to see if single and repeated doses are safe and tolerable in healthy, overweight, and obese adults. The study also tracks how the drug moves through the body and whether it affects body weight and related measures. Participants receive either IBI3042 or a placebo, with dose levels increasing as safety data allow.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- IBI3042, an investigational oral drug that activates the GLP-1 receptor
- What this could lead to
- If safe and effective, IBI3042 could become a convenient pill for weight management, offering an alternative to injectable GLP-1 drugs.
- What could go wrong
- This is a small, early-phase trial focused on safety, not proof of weight loss. The drug may fail in larger studies or cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 94 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged 18 to 55 years, inclusive. * For Part A: BMI ≥20 and\<28 kg/m\^2 and body weight ≥50 kg. * For Part B: BMI ≥24 and ≤40 kg/m\^2, with stable body weight during the 3 months prior to screening. * Female participants of childbearing potential and male participants with female partners of childbearing potential must agree to use highly effective contraception during the study and for 90 days after the last dose. * Able and willing to comply with study procedures and voluntarily provide written informed consent. Exclusion Criteria: * Known or suspected hypersensitivity to any component of the study drug or to GLP-1 receptor agonists. * History of diabetes or abnormal glycemic parameters at screening. * Personal or family history of thyroid C-cell carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2A or 2B), or calcitonin ≥20 ng/L at screening. * History of acute or chronic pancreatitis, or clinically significant pancreatic enzyme elevation at screening. * Use of medications that may significantly affect gastrointestinal motility, appetite, or drug absorption within 3 months prior to screening. * Clinically significant hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurologic disease that may increase study-related risk or interfere with study assessments. * Clinically significant abnormalities in physical examination or laboratory tests at screening. * History of malignancy within 5 years, except for basal cell or squamous cell skin cancer. * Use of prescription or over-the-counter medications, dietary supplements, or herbal medicines within 2 weeks or 5 half-lives prior to screening, except as permitted by the protocol. * Participation in another drug or medical device clinical study within 3 months prior to screening or within 5 half-lives of the investigational drug, as applicable. * Any other condition that, in the investigator's opinion, makes the participant unsuitable for participation in the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Heathy participants are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Hennan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- The acute effects of an endurance exercise bout the gut microbiome and gut-derived metabolome in Women's distinct fitness and body mass indexes
- Pilot study to evaluate the effect of nicotinamide riboside on immune activation in psoriasis
- The feasibility of electrical impedance tomography to guide non-invasive respiratory interventions in chronic respiratory disease
- Can a new injection help tackle obesity? a trial puts it to the test
- Does a Mother's weight change the chemistry of her breast milk?
- Can diverse tissue samples unlock Obesity's secrets?